34th week of 2015 patent applcation highlights part 22 |
Patent application number | Title | Published |
20150232497 | METHOD FOR ESTERIFYING LIGNIN WITH AT LEAST ONE FATTY ACID - The present invention relates to a method for producing lignin esterified with at least one fatty acid, wherein the method includes the following steps: (i) reacting acetylated lignin with at least one fatty acid under the influence of heating and distilling at least part of the acetic acid formed during the reaction away from the reaction mixture, wherein per each mole of acetyl groups present in the lignin an excess molar amount of at least one fatty acid is used; and (ii) recovering lignin esterified with at least one fatty acid formed in step (i). | 2015-08-20 |
20150232498 | ISOMERISATION OF C4-C6 ALDOSES WITH ZEOLITES - The present invention relates to isomerization of C4-C6 aldoses to their corresponding C4-C6 ketoses. In particular, the invention concerns isomerization of C4-C6 aldoses over solid zeolite catalysts free of any metals other than aluminum, in the presence of suitable solvent(s) at suitable elevated temperatures. C6 and C5 aldose sugars such as glucose and xylose, which are available in large amounts from biomass precursors, are isomerized to fructose and xylulose respectively, in a one or two-step process over inexpensive commercially available zeolite catalysts, containing aluminum as the only metal in the catalyst. The ketoses obtained are used as sweeteners in the food and/or brewery industry, or treated to obtain downstream platform chemicals such as lactic acid, HMF, levulinic acid, furfural, MMHB, and the like. | 2015-08-20 |
20150232499 | ANTI-INFLAMMATORY MACROLIDES - The invention provides novel compounds and compositions and methods for making and using the compounds and compositions. In particular, the use of organic acid salts promotes solubility. These more soluble forms are suitable for use in various diseases, notably diseases of lung, muscle, metabolism and eyesight. | 2015-08-20 |
20150232500 | PROCESSES FOR PREPARING MACROLIDES AND KETOLIDES AND INTERMEDIATES THEREFOR - The invention described herein pertains to processes for the preparation of macrolide antibacterial agents. In particular, the invention pertains to processes for preparing macrolides and ketolides from erythromycin A. | 2015-08-20 |
20150232501 | 2'-Ethynyl Nucleoside Derivatives for Treatment of Viral Infections - The present invention provides a compound of formula A: | 2015-08-20 |
20150232502 | Novel Neisseria gonorrhoeae therapeutic based on CMP-nonulosonate sugars - has become resistant to almost every conventional antibiotic. Described herein is the use of CMP-nonulosonate analogues to counter gonococcal complement evasion. The nonulosonate sugar is incorporated into the lipooligosaccharide of the | 2015-08-20 |
20150232503 | METHOD FOR PREPARING EXENATIDE - Disclosed in the present invention is a method for preparing Exenatide. Serine resin is obtained through a first coupling of serine and resin and successively with amino acids through a second coupling to obtain a peptide resin with a sequence as shown by SEQ ID No. 1; Exenatide resin is obtained through a third coupling of histidine containing a protecting group or salts thereof and the peptide resin with a sequence as shown by SEQ ID No. 1, then it is cracked and purified to obtain purified Exenatide peptide. The method for preparing Exenatide of the present invention inhibits the formation of D-His-Exenatide, and thereby improves the yield and purity of Exenatide. | 2015-08-20 |
20150232504 | ALDEHYDE CAPTURE LIGATION TECHNOLOGY FOR SYNTHESIS OF AMIDE BONDS - The present invention relates to ligation agents and their use in making an amide ligation product. Methods of making the ligation agents are also disclosed. | 2015-08-20 |
20150232505 | Integrated Continuous Manufacturing of Therapeutic Protein Drug Substances - Provided herein are integrated continuous biomanufacturing processes for producing a therapeutic protein drug substance. Also provided are systems that are capable of continuously producing a therapeutic protein drug substance. | 2015-08-20 |
20150232506 | POROUS HOLLOW FIBER MEMBRANE - A porous hollow fiber membrane is provided for the treatment of a protein-containing liquid, which can effectively separate and remove a substance such as a small diameter virus, and which can allow effective permeation of a useful substance to be recovered such as protein in high concentration. The porous hollow fiber membrane has an asymmetric structure having a dense layer in an outer layer only and contains a hydrophobic polymer and a first hydrophilic polymer, the surface and the porous part of the hollow fiber membrane are coated with a second hydrophilic polymer, the hydrophobic polymer is a polysulfone-type polymer, the first hydrophilic polymer is a copolymer of vinylpyrrolidone with vinyl acetate, and the second hydrophilic polymer is a polysaccharide or a polysaccharide derivative. The porous hollow fiber membrane is obtained by co-dissolving the hydrophobic polymer and the first hydrophilic polymer and then the second hydrophilic polymer is coated. | 2015-08-20 |
20150232507 | SPLIT INTEINS AND USES THEREOF - The present invention relates generally to robust split inteins. The split inteins described herein are active over a large temperature range, including temperatures as low as 0° C., over a wide pH range, and in the presence of chaotropic salts. The split inteins also show high tolerance to sequence variability in fused heterologous polypeptides and therefore are useful in protein purification and engineering techniques. | 2015-08-20 |
20150232508 | Bortezomib Esters And Formulations Thereof - Bortezomib esters with tartaric acid wherein the molar ratio between bortezomib and tartaric acid is 2:1 and formulations containing them are described. | 2015-08-20 |
20150232509 | SPIRO RING COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS - A compound of formula (I) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof is provided, which can be used for treating HCV infection or a HCV disorder. Also a pharmaceutical composition comprising the compound and the use of the compound and the pharmaceutical composition thereof are provided, which can also be used for treating HCV infection or a HCV disorder. | 2015-08-20 |
20150232510 | DIPEPTIDYL PEPTIDASE-IV INHIBITOR - An excellent peptidyl peptidase-IV inhibitor and the like are provided. A peptide consisting of Val-Pro-X wherein X represents an amino acid residue (except for L-proline residue); the aforementioned X is preferably one selected from a basic amino acid residue, an aliphatic neutral amino acid residue, an amide group-carrying neutral amino acid residue, or an aromatic group-carrying neutral amino acid residue; the aforementioned X is preferably one selected from an alanine residue, a glutamine residue, a methionine residue, an asparagine residue, a glycine residue, a valine residue, a tyrosine residue, a serine residue, and a lysine residue; a dipeptidyl peptidase-IV inhibitor, a blood sugar rise suppressing agent, a vascular endothelial disorder suppressing agent, and an angiotensin converting enzyme inhibitor containing the aforementioned peptide as an active ingredient. | 2015-08-20 |
20150232511 | METHOD FOR PRODUCING A COMPOSITION FOR TREATING A TOOTH LESION - The invention relates to a method for preparing a composition for treating a tooth lesion, said composition comprising peptides that are capable of undergoing self-assembly at a certain pH. The compositions of the invention are highly suitable for being used in the medical field, in particular for remineralising a tooth lesion such as a subsurface caries lesion. | 2015-08-20 |
20150232512 | SYNTHETIC PEPTIDE FOR ADJUSTING BALANCE BETWEEN PRESENCE OF TYPE 1 TNF RECEPTOR AND TYPE 2 TNF RECEPTOR AND USE THEREOF - Provided is a method for adjusting the balance of TNF-R1 and TNF-R2 in cells present at a target organ, tissue or site. In the adjustment method provided, when increasing the relative presence of TNF-R2 compared to the presence of TNF-R1 in the cells, a synthetic peptide is supplied to the cells, with the peptide being essentially made of at a TNF-R1 signal peptide motif or a modified amino acid sequence thereof; and when decreasing the relative presence of TNF-R2 compared to the presence of TNF-R1 in the cells, a synthetic peptide is supplied to the cells, with the peptide being essentially made of a TNF-R2 signal peptide motif or a modified amino acid sequence thereof. | 2015-08-20 |
20150232513 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B - The present invention provides compositions and methods for treating hepatitis B virus (HBV) infection as well as methods for identifying a compound or a composition that is suitable for treating HBV infection. In addition, the present invention provides a suitable non-mammalian animal model that can be used to screen for a compound or a composition that can inhibit HBV replication or treat HBV infection in a mammal. In particular, the present invention provides compositions and methods for treating hepatitis B infection by inhibiting interaction between HBV x protein and a Bcl-2 family protein or by reducing the expression level of a Bcl-2 family protein. | 2015-08-20 |
20150232514 | TFPI INHIBITORS AND METHODS OF USE - The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, and identify a TFPI-binding compound. | 2015-08-20 |
20150232515 | SALMONID ALPHAVIRUS AND USES THEREOF - This disclosure relates to reagents, methods for treating, diagnosing, and tracking diseases associated with salmon alphavirus. | 2015-08-20 |
20150232516 | Flagellin Fusion Proteins - Methods of making a protein that stimulates a protective immune response in a subject include separating a portion of a protein from a naturally occurring influenza viral hemagglutinin to form a protein portion. The protein portion includes at least a portion of a globular head, and at least a portion of at least one secondary structure having at least one β-sheet at a bottom of the globular head that causes the globular head to essentially retain its tertiary structure. The protein portion made by the methods of the invention lacks a transmembrane domain, a cytoplasmic domain and an HA2 subunit. A nucleic acid sequence encoding the protein portion is transformed into a prokaryotic host cell. | 2015-08-20 |
20150232517 | MUTANT FRAGMENTS OF OspA AND METHODS AND USES RELATING THERETO - The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a | 2015-08-20 |
20150232518 | TREATMENT OF MICROBIAL INFECTIONS - The present invention is directed to improved microbial antigen vaccines, pharmaceutical compositions, immunogenic compositions and antibodies and their use in the treatment of microbial infections, particularly those of bacterial origin, including Staphylococcal origin. Ideally, the present invention is directed to a recombinant staphylococcal MSCRAMM or MSCRAMM-like proteins, or fragment thereof, with reduced binding to its host ligand, for use in therapy. | 2015-08-20 |
20150232519 | MUTANT APOPROTEIN OF PHOTOPROTEIN WITH LOW CALCIUM SENSITIVITY - Calcium-binding photoproteins showing the luminescence pattern with a slow decay of are desired. The invention provides a mutant apoprotein comprising an amino acid sequence wherein the 23rd to 34th amino acids in the amino acid sequence of SEQ ID NO: 2 are substituted with an amino acid represented by formula I below: Xaa23-Xaa24-Xaa25-Xaa26-Xaa27-Xaa28-Xaa29-Xaa30-Xaa31-Xaa32-Xaa33-Xaa 34; having a function to bind to the peroxide of coelenterazine or the peroxide of a coelenterazine analogue to form a photoprotein capable of emitting light under the action of calcium ions; and, having a half decay time of the luminescence emitted by binding of the photoprotein to calcium ions being not less than 2 seconds. | 2015-08-20 |
20150232520 | Charged Nutritive Fragments, Proteins and Methods - Charged nutritive proteins provided. In some embodiments the nutritive proteins an aqueous solubility of at least 12.5 g/L at pH 7. In some embodiments the nutritive proteins an aqueous solubility of at least 50 g/L at pH 7. In some embodiments the nutritive proteins an aqueous solubility of at least 100 g/L at pH 7. In some embodiments the nutritive proteins comprise at least one of a level of a) a ratio of branch chain amino acid residues to total amino acid residues present in the nutritive protein equal to or greater than the ratio of branch chain amino acid residues to total amino acid residues present in a benchmark protein; b) a ratio of leucine residues to total amino acid residues present in the nutritive protein equal to or greater than the ratio of leucine residues to total amino acid residues present in a benchmark protein; and c) a ratio of essential amino acid residues to total amino acid residues present in the nutritive protein equal to or greater than the ratio of essential amino acid residues to total amino acid residues present in a benchmark protein. Also provided are nucleic acids encoding the proteins, recombinant microorganisms that make the proteins, methods of making the proteins using recombinant microorganisms, compositions that comprise the proteins, and methods of using the proteins, among other things. | 2015-08-20 |
20150232521 | PEPTIDES AND METHODS FOR INDUCING CELL DEATH - The invention provide isolated peptides, protides and conjugates having novel peptide sequences which are able to induce antimicrobial, anti-cancer, anti-inflammatory, anti-proliferative or programmed cell death activity. The invention also provides a method of inducing programmed cell death in a cell by contacting the cell with an isolated peptide, protide or conjugate described herein. In some aspects, the method can be used in the diagnosis, prevention, or treatment of a disease, such as an infection, cancer, autoimmune disease, or inflammatory disease. | 2015-08-20 |
20150232522 | BROWN ADIPOCYTE DIFFERENTIATION-INDUCING AGENT - The present invention addresses the problem of providing a means which is effective for the induction of the differentiation of a brown adipocyte and therefore enables a brown adipocyte to be used for and applied to, for example, the prevention/treatment of obesity or metabolic syndrome. Provided is a brown adipocyte differentiation-inducing agent containing, as an active ingredient, (1) CREG1 protein or (2) an expression vector carrying CREG1 gene. | 2015-08-20 |
20150232523 | USE OF PEDF-DERIVED POLYPEPTIDES FOR PREVENTING AND/OR AMELIORATING SKIN AGING - A method for preventing and/or ameliorating skin aging in a subject includes administering to the subject in need of such treatments a synthetic peptide, which has an amino acid sequence that has 20-39 amino acid residues. The synthetic peptide has at least 20 consecutive residues that has at least 90% amino acid sequence identity to residues 11-30 of SEQ ID NO: 1. | 2015-08-20 |
20150232524 | COMPOSITIONS AND METHODS RELATED TO DISEASES ASSOCIATED WITH DEPOSITS OF AMYLOID, TAU, AND ALPHA-SYNUCLEIN - Disclosed are compositions, comprising one or more immunogens, wherein each immunogen comprises at least two regions, wherein one region comprises at least one amyloid-β (Aβ) B cell epitope or at least one Tau B cell epitope or at least one α-synuclein B cell epitope or combinations thereof, and a second region comprises at least one foreign T helper cell (Th) epitope, and usually multiple foreign Th epitopes. Methods of making and using the compositions are also disclosed. | 2015-08-20 |
20150232525 | ANTI-TUMOUR RESPONSE TO MODIFIED SELF-EPITOPES - Anti-tumour immune responses to modified self-epitopes. The present invention relates to the use of tumour-associated epitopes in medicine and in particular in the treatment of cancer. The epitopes stimulate an immune reaction against the tumour and have a modification selected from deimination of arginine to citrulline, nitration of tyrosine, oxidation of tryptophan and deamination of glutamine or asparagine. The invention also relates to nucleic acids comprising sequences that encode such epitopes for use in the treatment of cancer. | 2015-08-20 |
20150232526 | USE OF RELAXIN TO TREAT ATRIAL FIBRILLATION - Disclosed herein are methods of using relaxin polypeptides and analogs, or nucleic acid molecules encoding such polypeptides to treat or inhibit atrial fibrillation. | 2015-08-20 |
20150232527 | GLUCAGON-LIKE PEPTIDE-1 ANALOGUE MONOMER AND DIMER, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF - Provided are a glucagon-like peptide-1 (GLP-1) analogue monomer and dimmer, a preparation method thereof, and an application thereof. The GLP-1 analogue monomer comprises one cysteine; and the dimer is formed by two monomer molecules connected via an intermolecular disulfide bond formed by the cysteine. The GLP-1 monomer comprising cysteine has the following general formula: | 2015-08-20 |
20150232528 | HIGH-EFFICIENCY, SODIUM -SPECIFIC, BLUE-SHIFTED CHANNELRHODOPSINS - Methods and compositions used to identify and characterize a new channelrhodopsin derived from algae which is highly efficient, sodium specific and blue-shifted. The rhodopsin domain of this channelrhodopsin can be cloned and expressed in mammalian systems and thus used in optogenetic applications and as therapeutic agents. | 2015-08-20 |
20150232529 | High Affinity TCR Proteins and Methods - T cell receptors (TCRs) that have higher affinity for a ligand than wild type TCRs are provided. These high affinity TCRs are formed by mutagenizing a T cell receptor protein coding sequence to generate a variegated population of mutants of the T cell receptor protein coding sequence; transforming the T cell receptor mutant coding sequence into yeast cells; inducing expression of the T cell receptor mutant coding sequence on the surface of yeast cells; and selecting those cells expressing T cell receptor mutants that have higher affinity for the peptide/MHC ligand than the wild type T cell receptor protein. The high affinity TCRs can be used in place of an antibody or single chain antibody. | 2015-08-20 |
20150232530 | METHOD FOR EXPRESSION OF SPECIFIC GENE - Disclosed is a cell which can express a non-natural oligomeric protein, which has, introduced therein, a gene encoding an exogenous polypeptide corresponding to at least one endogenous polypeptide constituting a natural oligomeric protein, and in which the expression of the endogenous polypeptide is inhibited. | 2015-08-20 |
20150232531 | INHIBITING PEPTIDES DERIVED FROM TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS-1 (TREM-1) TREM-LIKE TRANSCRIPT 1 (TLT-1) AND USES THEREOF - The present invention relates to a peptide comprising at least 6 consecutive amino acid selected from the amino acid sequence SEQ ID NO: 2 and a function-conservative variant. The invention also relates to a peptide comprising at least 6 consecutive amino acid selected from the amino acid sequence SEQ ID NO: 1 or SEQ ID NO: 2 and a function-conservative variant for use in the treatment of a cardiovascular disease. | 2015-08-20 |
20150232532 | SOLUBLE CD80 AS A THERAPEUTIC TO REVERSE IMMUNE SUPPRESSION IN CANCER PATIENTS - The present invention provides for a therapeutic cancer treatment using a soluble CD80 fusion protein that binds to PDL1 and inhibits PDL1-PD1 interactions thereby overcoming PDL1-induced immune suppression and restoring T cell activation. | 2015-08-20 |
20150232533 | B7-H1, A NOVEL IMMUNOREGULATORY MOLECULE - The invention provides novel polypeptides useful for co-stimulating T cells, isolated nucleic acid molecules encoding them, vectors containing the nucleic acid molecules, and cells containing the vectors. Also included are methods of making and using these co-stimulatory polypeptides. | 2015-08-20 |
20150232534 | COLLAGEN HYDROLYSATE AND USE THEREOF - The present invention relates to a collagen hydrolysate which is produced by enzymatic hydrolysis of type-B bone gelatin, wherein the collagen hydrolysate is formed from peptides of which at least 50% by weight, in particular at least 70% by weight have a molecular weight of 1,500 Da to 3,500 Da, and which have a mean molecular weight in the range from 4,000 Da to 8,000 Da, in particular in the range from 4,500 Da to 6,000 Da. The invention also relates to the use of this collagen hydrolysate as an active ingredient to maintain and/or improve the health of the bones, in particular to prevent and/or treat osteoporosis. The invention further relates to a nutritional supplement which comprises the collagen hydrolysate. | 2015-08-20 |
20150232535 | Production and Delivery of a Stable Collagen - Improved methods are provided for the recombinant synthesis of collagen, particularly collagen VII, in host cell, and for therapeutic delivery of the same. The recombinant collagen is produced in a host cell that has increased levels of prolyl-4-hydroxylase, relative to basal cell levels. The collagen produced by the methods of the invention has increased numbers of modified proline residues, relative to a recombinant collagen produced in a host cell having basal levels of prolyl-4-hydroxylase. The increased proline modification provides for a collagen having increased stability, including increased in vivo stability. | 2015-08-20 |
20150232536 | IgG STIMULATED REMYELINATION OF PERIPHERAL NERVES - The present invention is based on the discovery of polyclonal IgG's ability to promote Schwann cell maturation, differentiation, and myelin production. Methods for treating non-idiopathic, demyelinating peripheral neuropathies in mammals, where the neuropathy is not immune-mediated or infection-mediated, through the administration of polyclonal IgG are provided. Types of demyelinating peripheral neuropathies treatable with the present invention include peripheral nerve trauma and toxin-induced peripheral neuropathies. Alternatively, a composition of polyclonal IgGs can be applied directly to a peripheral nerve cell to induce maturation, differentiation into a myelinating state, and myelin expression or promote cell survival. | 2015-08-20 |
20150232537 | HUMAN BINDING MOLECULES CAPABLE OF BINDING TO AND NEUTRALIZING HEPATITIS B VIRUSES AND USES THEREOF - The disclosure relates to binding molecules, such as human monoclonal antibodies, that bind to Hepatitis B viruses, and have a broad neutralizing activity against such Hepatitis B viruses. The disclosure further provides nucleic acid molecules encoding the binding molecules, and compositions comprising the binding molecules. The binding molecules can be used in the diagnosis, prophylaxis and/or treatment of Hepatitis B. | 2015-08-20 |
20150232538 | Monoclonal Antibodies for Ebola and Marburg Viruses - Described herein are a number of Ebola monoclonal antibodies. | 2015-08-20 |
20150232539 | Methods and Compositions for Detecting, Imaging, and Treating Small Cell Lung Cancer Utilizing Post-Translationally Modified Residues and Higher Molecular Weight Antigenic Complexes in Proteins - The present invention discloses ectopically expressed isoaspartylated proteins and antigenic peptide fragments thereof as potential biomarkers for cancer such as small cell lung cancer. Also disclosed are antigen recognition agents capable of specifically recognizing and binding to isoaspartylated proteins and/or antigenic peptide fragments thereof. Antigen recognition agents of the invention may be formed from proteins, antibodies, RNA aptamers, or other small molecules capable of specifically binding to an isoaspartylated protein or an antigenic peptide fragment thereof. Other aspects disclosed herein include imaging methods for using the isoaspartyl antigen recognition agents, therapeutic methods for treating small cell lung cancer and compositions for performing the same. | 2015-08-20 |
20150232540 | ANALYSIS OF UBIQUITNATED POLYPEPTIDES - The disclosure relates to antibody reagents that specifically bind to peptides carrying a ubiquitin remnant from a digested or chemically treated biological sample. The reagents allow the technician to identify ubiquitinated polypeptides as well as the sites of ubiquitination on them. The reagents are preferably employed in proteomic analysis using mass spectrometry. The antibody reagents specifically bind to the remnant of ubiquitin (i.e., a diglycine modified epsilon amine of lysine) left on a peptide which as been generated by digesting or chemically treating ubiquitinated proteins. The inventive antibody reagents' affinity to the ubiquitin remnant does not depend on the remaining amino acid sequences flanking the modified (i.e., ubiquitinated) lysine, i.e., they are context independent. | 2015-08-20 |
20150232541 | METHOD FOR MAKING ANTIBODY FC-REGION CONJUGATES COMPRISING AT LEAST ONE BINDING ENTITY THAT SPECIFICALLY BINDS TO A TARGET AND USES THEREOF - Herein is reported a method for producing an antibody Fc-region conjugate comprising as first component an antibody Fc-region and as second component at least one binding entity that specifically binds to a target using a transpeptidase for enzymatic conjugation of the antibody Fc-region to at least one binding entity. | 2015-08-20 |
20150232542 | HUMAN ANTI-ALPHA-SYNUCLEIN ANTIBODIES - Provided are human alpha-synuclein-specific autoantibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for α-synuclein are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for α-synuclein targeted immunotherapy and diagnosis, respectively. | 2015-08-20 |
20150232543 | ACCEPTOR FRAMEWORK FOR CDR GRAFTING - The present invention relates to an antibody acceptor framework and to methods for grafting non-human antibodies, e.g., rabbit antibodies, using a particularly well suited antibody acceptor framework. Antibodies generated by the methods of the invention are useful in a variety of diagnostic and therapeutic applications. | 2015-08-20 |
20150232544 | METHODS OF TREATING A TAUOPATHY - The present disclosure provides methods of treating a tauopathy, involving administering an anti-Tau antibody. The present disclosure also provides anti-Tau antibodies, and formulations comprising same, for use in the methods. | 2015-08-20 |
20150232545 | HUMAN ANTIBODIES TO HUMAN DELTA LIKE LIGAND 4 - The present invention provides methods of treating, ameliorating, or inhibiting tumor growth, cancer, or pathological angiogenesis by administering to a subject in need thereof a human antibody or fragment thereof that specifically binds to human delta-like ligand 4 (hDll4) and blocks hDll4 binding to a Notch receptor. The anti-hDll4 antibody or fragment thereof of the present invention have a high affinity with the K | 2015-08-20 |
20150232546 | ANTI-PDGF-C ANTIBODIES - The invention relates to antibodies binding to the PDGF-C antigen and capable of inhibiting binding of PDGF-C to the PDGFRα receptor and of inhibiting PDGFRα activation by PDGF-C. Applications of such antibodies are also disclosed. These include treatment of cancer. | 2015-08-20 |
20150232547 | TREATMENT OF CANCER WITH ELEVATED DOSAGES OF SOLUBLE FGFR1 FUSION PROTEINS - The present invention provides methods of treating a patient having a cancer comprising administering to the patient a soluble Fibroblast Growth Factor Receptor 1 (FGFR1) fusion protein such as an extracellular domain of an FGFR1 polypeptide linked to an Fc polypeptide or another fusion partner. The fusion protein may be administered at a dose of at least about 2 mg/kg body weight. In some embodiments, the patient has a fibroblast growth factor-2 (FGF-2) plasma concentration of at least 6 pg/ml. In some embodiments, the cancer is characterized by a Fibroblast Growth Factor Receptor 2 (FGFR2) having a ligand-dependent activating mutation. | 2015-08-20 |
20150232548 | Combination therapy with an anti-ANG2 antibody and a CD40 agonist - The present invention relates to the combination therapy of an antibodies that binds to human angiopoietin 2 (ANG-2) with a CD40 agonist. | 2015-08-20 |
20150232549 | ANTI-VEGF ANTIBODIES - Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications. | 2015-08-20 |
20150232550 | DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF - Engineered multivalent and multispecific binding proteins, methods of making, and their uses in the prevention, diagnosis, and/or treatment of disease are provided. | 2015-08-20 |
20150232551 | ANTIBODIES DIRECTED TO IL-17A/F HETEROLOGOUS POLYPEPTIDES AND THERAPEUTIC USES OF THEREOF - The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17F designated herein as interleukin 17A/F (IL-17A/F). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, specific antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases. | 2015-08-20 |
20150232552 | ANTIBODIES THAT BIND IL-23 - The present invention provides an antibody that binds to the p19 subunit of human IL-23 and is characterized as having high affinity, selective, and neutralizing properties. The antibody is useful in the treatment or prevention of an autoimmune or inflammatory condition selected from the group consisting of consisting of multiple sclerosis, rheumatoid arthritis, psoriasis, inflammatory bowel diseases, ankylosing spondylitis, graft-versus-host disease, lupus and metabolic syndrome. The antibody is also useful in the treatment of cancer. | 2015-08-20 |
20150232553 | FUNCTION MODIFYING NAv1.7 ANTIBODIES | 2015-08-20 |
20150232554 | FRIZZLED-BINDING AGENTS AND USES THEREOF - Novel anti-cancer agents, including, but not limited to, antibodies, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using the agents or antibodies to inhibit Wnt signaling and/or inhibit tumor growth are further provided. | 2015-08-20 |
20150232555 | ANTIBODIES TO HUMAN PROGRAMMED DEATH RECEPTOR PD-1 - Antibodies which block binding of hPD-1 to hPD-L1 or hPD-L2 and their variable region sequences are disclosed. A method of increasing the activity (or reducing downmodulation) of an immune cell through the PD-1 pathway is also disclosed. | 2015-08-20 |
20150232556 | KIR3DL2 BINDING AGENTS - The present invention relates to methods for the treatment of cancer and inflammatory disease using antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind KIR3DL2. The invention also relates to antibodies, cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same. | 2015-08-20 |
20150232557 | CD3 BINDING POLYPEPTIDES - The present invention relates to mono-specific and multi-specific polypeptides that specifically bind or interact with CD3. These polypeptides can be, but are not limited to, antibodies, fragments thereof, scFvs, Fabs, di-scFvs single domain antibodies, diabodies, dual variable domain binding proteins and polypeptides containing an antibody or antibody fragments. In one embodiment, a multi-specific polypeptide binds both a T-cell receptor complex on T-cells and a tumor antigen to induce target-dependent T-cell cytotoxicity, activation and proliferation. | 2015-08-20 |
20150232558 | STIMULATING BONE FORMATION BY INHIBITION OF CD28 CO-STIMULATION - The disclosure relates to methods of growing bone or increasing bone mineral density and/or volume comprising administering an effective amount of a therapeutic containing abatacept or belatacept or other molecule that binds with CD8O, CD86, or CD28 providing inhibition of CD28 co-stimulation to a subject in need thereof. | 2015-08-20 |
20150232559 | ANTI-ALPHA2 INTEGRIN ANTIBODIES AND THEIR USES - The invention relates to antibodies directed to α2β1 integrin and their uses, including humanized anti-alpha 2 (α2) integrin antibodies and methods of treatment with anti-α2 integrin antibodies. More specifically the present invention relates to humanized anti-α2 integrin antibodies comprising a heavy chain variable region, a light chain variable region, a human light chain constant region and a variant human IgG1 heavy chain constant region which exhibit altered effector function. | 2015-08-20 |
20150232560 | METHOD FOR THE SELECTION AND PRODUCTION OF TAILOR-MADE, SELECTIVE AND MULTI-SPECIFIC THERAPEUTIC MOLECULES COMPRISING AT LEAST TWO DIFFERENT TARGETING ENTITIES AND USES THEREOF - Herein is reported a method for determining a combination of antigen binding sites comprising the steps of (i) determining the binding specificity and/or affinity and/or effector function and/or in vivo half-life of a multitude of bispecific antibodies prepared by combining each member of a first multitude of antibody Fab fragments or scFv antibody fragments with each member of a second multitude of antibody Fab fragments or scFv antibody fragments, and a linker comprising at one of its termini the second member of the first binding pair and at the respective other terminus the second member of the second binding pair, whereby the first multitude specifically binds to a first cell surface molecule and the second multitude specifically binds to a second cell surface molecule, and (ii) choosing the bispecific antibody with suitable binding specificity and/or affinity and/or effector function and/or in vivo half-life and thereby determining a combination of antigen binding sites. | 2015-08-20 |
20150232561 | METHOD FOR SELECTION AND PRODUCTION OF TAILOR-MADE HIGHLY SELECTIVE AND MULTI-SPECIFIC TARGETING ENTITIES CONTAINING AT LEAST TWO DIFFERENT BINDING ENTITIES AND USES THEREOF - Herein is reported a method for producing a bispecific antibody comprising the step of incubating
| 2015-08-20 |
20150232562 | AMINO ACID SEQUENCES DIRECTED AGAINST HER2 AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF CANCERS AND/OR TUMORS - The present invention relates to amino acid sequences and Nanobodies that are directed against Epidermal Growth Factor Receptor 2 (HER2), as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. | 2015-08-20 |
20150232563 | NOVEL MUTATED HUMANIZED 12G4 ANTIBODIES AND THE FRAGMENTS THEREOF AGAINST THE HUMAN ANTI-MULLERIAN HORMONE RECEPTOR TYPE II - Novel mutated humanized 12G4 antibodies, and fragments thereof, directed against the anti-Müllerian hormone type II receptor. | 2015-08-20 |
20150232564 | REGULATING IL-4 AND IL-13 LEVELS BY BLOCKING HIGH AFFINITY BINDING BY IL-3, IL-5 AND GM-CSF TO THEIR COMMON RECEPTOR - A method of reducing IL-4 and/or IL-13 levels in the lung of a mammal with elevated levels thereof, includes the step of administering to the mammal an effective amount of a βc receptor blocker capable of blocking the binding of all three of IL-3, IL-5 and GM-CSF to the βc common chain to thereby reduce the IL-4 and/or IL-13 levels. | 2015-08-20 |
20150232565 | Modulation of Activity of Neurotrophins - The present invention relates to methods for modulating the activity of one or more neurotrophins, such as neural growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin-3, and neurotrophin-4 (NT-4), in an animal and methods for treatment of a disease or disorder in an individual by modulation of neurotrophin activity. The modulation is carried out by interfering with binding between a neurotrophin and a receptor of the Vps10p-domain receptor family or modulating the expression of a receptor of the Vps10p-domain receptor family. Methods for screening for agents capable of modulating neurotrophin activity and agents selected using these screening methods are also disclosed, as are methods for determining the effect of an agent on one or more neurotrophins in cells. The present invention also pertains to methods for modulating the transport of one or more neurotrophins. | 2015-08-20 |
20150232566 | CARRIER IMMUNOGLOBULINS AND USES THEREOF - Disclosed is an isolated immunoglobulin. Also disclosed are pharmaceutical compositions and medicaments comprising the immunoglobulin, isolated nucleic acid encoding it, vectors, host cells, useful in methods of making it. In some embodiments the immunoglobulin comprises one to twenty-four pharmacologically active chemical moieties conjugated thereto, such as a pharmacologically active polypeptide. | 2015-08-20 |
20150232567 | Fc Variants with Increased Affinity for FcyRIIc - The present invention relates to Fc variants having increased affinity for FcγRIIc, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants. | 2015-08-20 |
20150232568 | ANTI-JAGGED ANTIBODIES AND METHODS OF USE - The disclosure provides anti-Jagged antibodies and methods of using the same. | 2015-08-20 |
20150232569 | ANTIBODIES AND VACCINES FOR USE IN TREATING ROR1 CANCERS AND INHIBITING METASTASIS - The present invention relates to pharmaceutical compositions and a method of inhibiting metastasis using anti-ROR1 antibodies or antigen binding fragments, ROR1 binding peptides and ROR1 vaccines. | 2015-08-20 |
20150232570 | Methods of Treating Hematological Malignancies with Notch1 Antibodies - NOTCH1-binding antibodies and methods of using the antibodies for treating hematologic cancers are disclosed. Methods of using antibodies that bind to a non-ligand binding membrane proximal region of the extracellular domain of human NOTCH1 and methods of treating chronic lymphocytic leukemia (CLL), hairy cell leukemia, chronic myelogenous leukemia (CML), nonHodgkin lymphoma, diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), or cutaneous T-cell lymphoma (CTCL) in a subject, comprising administering a therapeutically effective amount of a NOTCH1-binding antibody to the subject are also disclosed. Methods of identifying subjects suitable for such treatment methods are further disclosed. | 2015-08-20 |
20150232571 | ANTI-CD38 HUMAN ANTIBODIES AND USES THEREFOR - The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These antibodies, accordingly, can be used to treat, for example, hematological malignancies such as multiple myeloma. Antibodies of the invention also can be used in the diagnostics field, as well as for investigating the role of CD38 in the progression of disorders associated with malignancies. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use. The invention also provides isolated novel epitopes of CD38 and methods of use therefore. | 2015-08-20 |
20150232572 | COMBINATION TREATMENT OF CANCER - The present invention provides MT4-MMP inhibitor and EGFR inhibitor for use in the treatment of cancer, wherein said MT4-MMP inhibitor and EGFR inhibitor are different from each other. MT4-MMP (MMP-17) is a glycosylphosphatidyl inositol (GPI) anchored MMP produced by cancer cells that promotes tumor vascularization and metastases. The present invention found that MT4-MMP expression promotes cancer cell proliferation. These effects involve retinoblastoma protein (Rb) inactivation, cyclin dependent kinase CDK4 activation and Epidermal Growth Factor Receptor (EGFR) signaling. Co-immuno-precipitations indicate the existence of protein complexes harboring MT4-MMP and EGFR. The present invention further found a novel mechanism of MT4-MMP action through an outside-in signaling involving EGFR. An unexpected crosstalk between an MMP and EGFR was identified and recognized as a key driver of cancer cell biology. | 2015-08-20 |
20150232573 | ANTI-EGFR/ANTI-HER2 BISPECIFIC ANTIBODIES WITH ANTI-EGFR DARPINS - An anti-EGFR/anti-HER2 bispecific antibody including an anti-EGFR DARPin and an anti-HER2 antibody, a pharmaceutical composition including the bispecific antibody, a method of preparing the bispecific antibody, and a method of reducing a side effect and/or enhancing efficacy of an anti-HER2 antibody using an anti-EGFR DARPin. | 2015-08-20 |
20150232574 | PREDICTIVE MARKER FOR TOPOISOMERASE I INHIBITORS - The present invention generally relates to the fields of cancer therapy and cancer prevention. More particularly, the present invention generally relates to a diagnostic marker for predicting the efficacy of topoisomerase I (topo I) inhibitors in the treatment of cancers. More specifically, the present invention relates to methods, machines, computer systems, computable readable media and kits which can be used to identify and determine the effectiveness of topoisomerase I (topo I) inhibitors in the treatment of cancers, and in some embodiments, the level of sensitivity or resistance of a tumor cell to a topoisomerase I inhibitor, such as camptothecin (CPT), or CTP analogues such as topotecan and irinotecan and derivatives thereof. More specifically, the present invention related to methods, machines, computer systems, computable readable media and kits which can be used to determine the presence of phosphorylation of topoisomerase I polypeptide, in some embodiments phosphorylation at residue serine 10 (S10) of a topoisomerase I polypeptide, wherein the presence of phosphorylation, in particular the phosphorylation at serine 10 of a topoI polypeptide indicates a cancer is likely to be unresponsive to a topo I inhibitor, whereas the absence of phosphorylation, in particular, the absence of phosphorylation at residue serine 10 (S10) identifies a cancer is likely to be responsive to a topo I inhibitor. Other aspect of the present invention relate to phospho-serine10 topoisomerase I antibodies and other protein binding moieties, and uses thereof. | 2015-08-20 |
20150232575 | TREATMENT OF OCULAR DISEASES - Disclosed are methods for treating eye diseases or conditions characterized by vascular instability, vascular leakage and neovacularization such as diabetic macular edema, age-related macular edema, choroidal neovascularization, diabetic retinopathy, trauma, ocular ischemia, retinal angiomatous proliferation, macular telangiectasia and uveitis. | 2015-08-20 |
20150232576 | ENDOTHELIAL NITRIC OXIDE SYNTHASE - Endothelial nitric oxide synthase (eNOS) activity was modulated by contact with an effective amount of a mitogen-activated protein (MAP) kinase, resulting in phosphorylation of S602, T46, and/or S58. Kinetics and stoichiometry are disclosed. The contact strongly reduced nitric oxide (NO) synthesis, and inhibited the cytochrome c reductase activity of eNOS reductase domains. Three sites of phosphorylation were determined that matched the serine-proline (SP) and threonine-proline (TP) motifs of typical MAP kinase phosphorylation sites. | 2015-08-20 |
20150232577 | ANTI-BIOTIN ANTIBODIES AND METHODS OF USE - The invention provides anti-biotin antibodies and methods of using the same. | 2015-08-20 |
20150232578 | HYBRID PROTEINS AND USES THEREOF - There are disclosed hybrid proteins comprising at least one signal sequence; at least one DNA binding domain; and at least one cell penetrating peptide (CPP) domain. In embodiments the CPP domain is a TAT domain, and the DNA binding domain is a HU domain. There is also disclosed the use of the hybrid proteins to introduce exogenous DNA into target cells, and methods for introducing exogenous DNA into target cells using the hybrid proteins. | 2015-08-20 |
20150232579 | METHOD AND APPARATUS FOR CONVERSION OF CELLULOSIC MATERIAL TO ETHANOL - The present invention provides an apparatus and a method for conversion of cellulosic material, such as chopped straw and corn stover, and household waste, to ethanol and other products. The cellulosic material is subjected to continuous hydrothermal pre-treatment without addition of chemicals, and a liquid and a fibre fraction are produced. The fibre fraction is subjected to enzymatic liquefaction and saccharification. The method of the present invention comprises:
| 2015-08-20 |
20150232580 | PROCESSES AND APPARATUS FOR REMOVAL OF FERMENTATION INHIBITORS FROM BIOMASS HYDROLYSATES - The disclosure provides a process for separating fermentation inhibitors from a biomass-derived hydrolysate, comprising: introducing a biomass-derived liquid hydrolysate stream to a stripping column; introducing a steam-rich vapor stream to the stripping column to strip fermentation inhibitors (such as acetic acid) from the liquid hydrolysate stream; recovering a stripped liquid stream and a stripper vapor output stream; compressing the stripper vapor output stream; introducing the compressed vapor stream, and a water-rich liquid stream, to an evaporator; recovering, from the evaporator, an evaporated liquid stream and an evaporator output vapor stream; and recycling the evaporator output vapor stream to the stripping column as the steam-rich vapor stream. Other variations utilize a rectification column to recover a rectified liquid stream and a rectification column vapor stream, and recycle the rectification column vapor stream to the stripping column as the steam-rich vapor stream. | 2015-08-20 |
20150232581 | Methods for Purifying Polysaccharides and Pharmaceutical Compositions and Medical Devices Containing the Same - Methods for removing endotoxin from naturally occurring materials, such as polysaccharides (e.g., agarose and/or carrageenan) are described herein. Polysaccharides that are substantially free of endotoxins and uses thereof are also described. The polysaccharide materials can be isolated from microorganisms, multicellular organisms, such as, algae, plants, seaweed, etc. The method involves the use of acidic and basic solutions to hydrolyze the lipid-polysaccharide bond in endotoxins. Cleaving the fatty acid from the polysaccharide reduces the water-solubility of the fatty acid and enables its removal with an organic solvent such as ethanol. The polysaccharide component can also undergo acidic or basic hydrolysis due to the weak glycosidic bond between the sugar rings. | 2015-08-20 |
20150232582 | Hemicellulose Compositions - Hemicellulose compositions are prepared by treating a cellulosic material with an extractant comprising a cellulose solvent and co-solvent. The hemicellulose compositions preferably comprise from 55 to 99 wt. % xylan and have distinct molecular weights, elemental metal ions, and intrinsic viscosities when compared to known hemicellulose compositions. | 2015-08-20 |
20150232583 | PROCESSES AND METHODS FOR EXTRACTING RUBBER FROM GUAYULE - Improved methods and processes of extracting rubber from guayule and guayule-like fibrous plant material are disclosed herein in. The methods and process advantageously may include the step of drying the plant material to a moisture content of about 18% to about 36% to produce a feedstock, performing at least a first grind of the feedstock, optionally adding an antioxidant to the feedstock, combining an extraction solvent with the feedstock after the antioxidant has been added to the feedstock to form a miscella, and recovering rubber from the miscella. | 2015-08-20 |
20150232584 | TANDEM METATHESIS AND HYDROGENATION OF DIENE-BASED POLYMERS IN LATEX - The present invention provides a novel process for subjecting a diene-based-polymer to a metathesis reaction in a first step and a selective hydrogenation of the carbon-carbon double bonds present in such diene-based polymers in a second step using a ruthenium or osmium based complex catalyst, wherein the diene-based polymer is present in latex form, this means as a suspension of diene-based polymer particles in an aqueous medium. | 2015-08-20 |
20150232585 | HYDROGENATION OF DIENE-BASED POLYMER LATEX IN THE PRESENCE OF AN IN SITU SYNTHESIZED CATALYST - A technique of improving the hydrogenation reaction of diene-based polymers, present in aqueous suspension, by in-situ synthesizing the catalyst in the presence of a specific aliphatic alcohol is disclosed. The process allows the selective hydrogenation of the carbon-carbon double bonds in the diene-based polymers with a high degree of hydrogenation and short reactions times. The improved process eliminates the complicated catalyst synthesis operations so far necessary. | 2015-08-20 |
20150232586 | CROSSLINKED POLYETHYLENE COMPOSITION - A crosslinked polyethylene composition comprising 100 parts by weight of polyethylene, 0.05-5 parts by weight of crosslinking agent, 0.03-3 parts by weight of crosslinking aid. Polyethylene is a copolymer, homopolymer and/or a mixture thereof. The crosslinking agent is an organic peroxide having a half-life period longer than 3 minutes at 190° C. and/or a multi-membered heterocyclic alkane consisting of 3 to 6 carbon atoms and 3 to 6 oxygen atoms and/or a derivative thereof. The crosslinking aid is an organic substance containing allyl, maleimido, (meth)acrylate group and/or a polymer having a vinyl content higher than 50%. Preferably, the crosslinking aid is triallyl isocyanate (TAIC), triallyl cyanurate (TAC) or a mixture thereof. The crosslinked polyethylene composition has a crosslinking efficiency index >1000 Nm/g and a δ torque value >15 Nm at 220° C., and has a high safe processing temperature and long crosslinking delay, and therefore is particularly suitable for rotationally molded products. | 2015-08-20 |
20150232587 | Maleic Anhydride Functionalization of Polypropylene via Solid-State Shear Pulverization - Functionalization of polymers, including polyolefins, with a, β-unsaturated carboxy-derived moieties through the use of solid-state shear pulverization. | 2015-08-20 |
20150232588 | PROCESS FOR THE GAS-PHASE POLYMERIZATION OF OLEFINS - A process and apparatus for producing olefin polymers are disclosed, comprising: | 2015-08-20 |
20150232589 | Ethylene-Based Polymers and Articles Made Therefrom - Ethylene-based copolymers having unusual viscosity performance are described, particularly ethylene-based polymers having about 80.0 to 99.0 wt. % of polymer units derived from ethylene and about 1.0 to about 20.0 wt. % of polymer units derived from one or more C | 2015-08-20 |
20150232590 | COMPOSITION OF ORGANIC PEROXIDE WITHOUT A COLLOID AGENT - An aqueous emulsion composition of organic peroxide without a protective colloid agent wherein the emulsifying agent is a nonionic surfactant chosen exclusively from a block copolymer including at least one alkylene oxide block, a block copolymer including at least two alkylene oxide blocks, an alkoxylated fatty alcohol, an alkoxylated fatty acid, an alkoxylated vegetable or animal oil (hydrogenated or not) or a mixture of a plurality of these elements. Also, a method for producing this composition and specific uses thereof. | 2015-08-20 |
20150232591 | (METH)ACRYLATE COMPOSITION - Presented is a (meth)acrylate composition that can be cured even in an unirradiated portion that is not reached by light. The (meth)acrylate composition contains a compound having one or more vinyl groups in a molecular structure thereof. The compound has a ratio of a molecular weight thereof to a number of the vinyl groups of 300 or lower. The composition generates a heat of reaction during photopolymerization thereof, and the heat of reaction causes thermal polymerization of the composition. | 2015-08-20 |
20150232592 | RIGID AND CONTORTED DIVINYL CROSSLINKERS - Polymerizable compositions containing rigid and contorted divinyl crosslinkers and polymeric materials prepared from the polymerizable compositions are described. The crosslinkers have a spirobisindane-type structure and can undergo free radical polymerization reactions. Methods of preparing the polymeric materials from the polymerizable compositions are also described. | 2015-08-20 |
20150232593 | TETRAFLUOROETHYLENE COPOLYMERS - The invention pertains to a tetrafluoroethylene (TFE) copolymer comprising recurring units derived from at least one perfluoroalkyl(oxy)vinylether of formula CF | 2015-08-20 |
20150232594 | NOVEL PROCESS - The present invention relates to a novel process for the preparation of acrylic polymer beads, said process encompassing the step of washing the acrylic polymer beads with purified water. | 2015-08-20 |
20150232595 | RESIN MIXTURE BASED ON VINYL ESTER RESIN, REACTIVE RESIN MORTAR COMPRISING SAME AND USE THEREOF - Described is a resin mixture comprising a vinyl ester resin and a co-polymerizable compound, which bears at least two methacrylate groups, some of which is replaced by an itaconic acid ester. It is possible to control the properties of the composition, such as the curing, through the selection of the itaconic acid ester. In addition and beyond this feature, it is possible to formulate resin compositions that exhibit a certain amount of bio-based carbon. | 2015-08-20 |
20150232596 | CROSSLINKABLE COMPOSITION COMPRISING PHOTOBASE GENERATORS - The present disclosure provides an crosslinkable composition comprising a (meth)acrylate copolymer component having pendant photobase functional groups and a crosslinking agent that has amine-reactive functional groups. On exposure to light, the pendant photobase group photolyzes to provide a pendant amine group, that crosslinks the copolymer. | 2015-08-20 |